Daniel Barber, CEO, highlighted increased awareness for the Anaphylm sublingual film program, stating, "most allergists are now aware of our sublingual film program and over 25% have even completed ...
CEO Kabir Nath highlighted "the potential 9- to 12-month acceleration of our launch plans that we announced today" as a key update, citing the completion of enrollment for the COMP006 Phase III trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback